No abstract available.
Erythrocytes*

PURPOSE: Carcinoma of the gallbladder is an aggressive, late-symptomatic disease and most patients are treated at an advanced stage, and these patients have a poor prognosis. During recent years, extended operations that combine a resection of the liver with wide lymph node dissection have improved the long-term survival. The aim of this study is to evaluate the surgical outcome for gallbladder carcinoma based on the presence of lymph node metastasis and the depth of the primary tumor invasion. METHODS: A retrospective analysis was done on 68 patients who underwent a surgical resection of gallbladder carcinoma from 1997 to 2004. The factors that nfluenced the 5-year survival were examined. RESULTS: The overall 5-year survival rate was 49.6%. The lymph node metastasis rate was 40.0% in T2 disease and 61.1% in T3/T4 disease. The 5-year survival rate (5-YSR) for T2 disease was 52.1% for the patients who underwent cholecystectomy with lymph node dissection and hepatic resection, and it was 51.2% for the patients who underwent only simple cholecystectomy. The 5-YSR for T3/T4 disease was 33.3% for the patients who underwent extended cholecystectomy, and it was 12.9% for the palliative cholecystectomy patients. CONCLUSION: The role of radical surgery seems to be limited for patients with more extensive tumor invasion or lymph node metastasis.
Cholecystectomy ; Gallbladder ; Gallbladder Neoplasms ; Humans ; Liver ; Lymph Node Excision ; Lymph Nodes ; Neoplasm Metastasis ; Prognosis ; Retrospective Studies ; Survival Rate

No abstract available.
Hemorrhage*

No abstract available.
Child ; Child Development* ; Humans ; Infant* ; Mass Screening*

No abstract available.
Humans ; Siblings*

High pre-transplant isoagglutinin is a risk factor for antibody-mediated rejection in ABO-incompatible living donor liver transplantation. A 55-year-old man with alcoholic liver cirrhosis underwent ABO-incompatible living donor liver transplantation. The initial isoagglutinin immunoglobulin G titer was 1:1,024. Despite five sessions of plasmapheresis, the isoagglutinin titer was not significantly reduced (from 1:1,024 to 1:512). We decided to perform 11 plasmaphereses and proceed with liver transplantation regardless of the isoagglutinin titer (1:128 at transplantation day). Instead, we planned to administer 0.5 g/kg intravenous immunoglobulin and booster rituximab (200 mg) after transplant. On postoperative day 6, the isoagglutinin titer increased from 1:32 to 1:64, and the patient received plasmapheresis twice. The patient maintained stable liver function without evidence of further complications or rejection. The high-dose intravenous immunoglobulin, salvage plasmapheresis, and booster rituximab protocol might be able to overcome a pre-transplant high isoagglutinin titer in ABO-incompatible living donor liver transplantation without splenectomy.

Refractory ascites is a rare complication after liver transplantation, and its incidence ranges from 5% to 7%. A 56-yearold man diagnosed with HBV-LC with massive ascites underwent living donor liver transplantation. After transplantation, more than 1000 ml/day of ascites was steadily drained until two weeks after LT. CT showed intrahepatic Rt. portal vein thrombosis and many remnant collaterals with splenomegaly. We decided to embolize the proximal splenic artery and use apixaban to reduce portal flow and resolve the intrahepatic portal thrombosis. One day after splenic artery embolization, the patient's ascites dramatically decreased. Three days later, he was discharged from the hospital. Three months later, a follow-up liver CT showed resolution of thrombosis and no ascites. Splenic artery embolization was an effective and safe procedure for portal flow modulation in portal hyertension. Apixaban was effective for partial portal vein thrombosis in a liver transplant recipient.

No abstract available.
Diagnosis* ; Hemophilia A* ; Molecular Biology* ; Polymorphism, Restriction Fragment Length*

No abstract available.
Cervix Uteri* ; Female ; Humans ; Mass Screening* ; Uterine Cervical Neoplasms*

No abstract available.
Cystadenocarcinoma, Mucinous* ; Mucins*